RxDoctor Payments Data

Leah Colby

Optometrist · Rogers, MNNPI 1942292727

Payments from drug & device makers

$1,322in general payments, 2019–2025

Across 37 payments — averaging $35.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$874
  • Alcon$153
  • Coopervision Inc.$87
  • Oyster Point Pharma, Inc.$58
  • Carl Zeiss Meditec AG$39
  • Biotissue Holdings Inc.$32
  • plus $80 from 5 others

What the payments were for

  • Consulting fees$59345%
  • Food & beverage$69052%
  • Gifts$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,322 in reported general payments places this provider in the 85th percentile of 826 optometrist providers in Minnesota.

See all optometrist providers in Minnesota

Medicare billing

Part B allowed, 2024
$25,901
Medicare patients
151
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$25,873
Cyclosporine13$4,895
Brimonidine Tartrate33$2,814
Latanoprost100$1,940
Timolol Maleate38$1,626
Prednisolone Acetate12$535
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$484
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha31$416
Dorzolamide Hcl27$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$13$25,87319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 826 optometrist providers in Minnesota.

Other optometrist in Rogers

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →